Advanced Life Sciences to Host Conference Call to Discuss Data From,Cethromycin's First of Two Phase 3 Pneumonia Trials ( CHICAGO June 29 2007 /PRNewswire-Fir...)

Advanced Life Sciences to Host Conference Call to Discuss Data From,Cethromycin's First of Two Phase 3 Pneumonia Trials

CHICAGO, June 29, 2007 /PRNewswire-FirstCall/ -- Advanced Life Sciences Holdings, Inc. , today announced that it will host a conference call and live webcast at 10:00 am (EDT) on Monday, July 2, 2007 to discuss data from Trial CL-06, the first of two pivotal Phase 3 clinical trials designed to assess the safety and effectiveness of cethromycin, a novel once-a-day antibiotic, for the treatment of community acquired pneumonia (CAP).

Conference Call Details:

The conference call will be webcast simultaneously over the Internet. Please visit the Investor Relations section of the Advanced Life Sciences corporate website http://www.advancedlifesciences.com. Alternatively, callers may participate in the conference call by dialing 800-561-2601(domestic) or 617-614-3518 (international). The passcode for the conference call is 84510433. A replay of the conference call will be available until August 2, 2007. Callers may access the telephone replay by dialing 888-286-8010 (domestic) or 617-801-6888 (international), passcode 90055877.

About Advanced Life Sciences

Advanced Life Sciences is a biopharmaceutical company engaged in the discovery, development and commercialization of novel drugs in the therapeutic areas of infection, cancer and inflammation. The Company's lead candidate, cethromycin, is a novel once-a-day antibiotic in late-stage clinical development for the treatment of respiratory tract infections including CAP. For more information, please visit us on the web at http://www.advancedlifesciences.com.

Forward-Looking Statements

Any statements contained in this press release that relate to future plans, events or performance are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forw
'"/>

Page: 1 2
Related medicine technology :

1. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
2. BusinessWeek Article Highlights Promising Breakthrough Treatment for Advanced Coronary Artery Disease
3. BusinessWeek Article Highlights Promising Breakthrough Treatment for Advanced Coronary Artery Disease
4. Advanced Life Sciences Announces Supplemental Efficacy Data from First Pivotal Phase 3 Pneumonia Clinical Trial
5. Progenics and Wyeth Announce Positive Results from Three-Month Clinical-Extension Study of Subcutaneous Methylnaltrexone for the Treatment of Opioid-Induced Constipation in Patients with Advanced Illness
6. Advanced Cell Technology Develops First Human Embryonic Stem Cell Line without Destroying an Embryo
7. Neurologix Announces Publication of Landmark Gene Therapy Study Demonstrating Safety and Statistically Significant Improvement in Patients With Advanced Parkinsons Disease
8. Advanced Viral Research Corp. Announces Positive Preliminary Findings from Ongoing Phase II Dermatological Study
9. Clinical Data Reported on Vidaza in Hematologic Malignancies and Advanced Solid Tumors
10. Updated Study Results Reinforce Survival Benefit of Taxotere (Docetaxel) for Men with Advanced, Hormone-Resistant Prostate Cancer
11. GSKS Pazopanib Shows Positive Results in Patients with Advanced Renal Cell Carcinoma, Ovarian Cancer and Soft Tissue Sarcoma

Post Your Comments:

(Date:11/20/2009)... , NEW YORK, Nov. 20 Repo...report is available in its catalogue. ,, Blood... - A World Market Analysis ,, http://www.rep...Measurement-Instruments---A-World-Market-Analysis....tm_campaign=prnewswire ,, Measurement of bloo...

(Date:11/20/2009)... , NEW YORK, Nov. 20 ,...search report is available in its catalogue. ,,...casts to 2015 ,, http://www.reportlinker.com...and-Forecasts-to-2015.html#utm_source=prnewswire&a..., Description ,, India Medical Equipment Mar...

(Date:11/20/2009)... , NEW YORK, Nov. 20 Repo...report is available in its catalogue. ,, Medic..., http://www.reportlinker.com/p0164242/Medical...utm_source=prnewswire&utm_medium=pr&utm_ca...ives and sealants is gaining preeminence in medica...

[0] Reportlinker Adds Blood Pressure Monitoring & Measurement Instruments - A World Market Analysis [0] Reportlinker Adds India Medical Equipment Market Analysis and Forecasts to 2015 [0] Reportlinker Adds Medical Adhesives and Sealants - A US Market Review

...cational Symposium as Xoft, Launches New Oncology ...x Vehicles, BOSTON...,Electronic Brachytherapy (eBx) System, which deli...o cancer sites with minimal radiation exposure,to ...inical experience with,its growing suite of oncolo...

...any,focused on developing novel therapeutics for s...ments to add commercial and manufacturing expertis...nction with the recent,initiation of two clinical ...atasia., Julie Anne Smith has been appointed as E...and Jayant Aphale, PhD., MBA has been appointed as...

Other Medicine Technology:Xoft Showcases Interim Clincal Results for Breast Cancer Product and New Indications for Electronic Brachytherapy(eBx) at Astro Meeting 2 Xoft Showcases Interim Clincal Results for Breast Cancer Product and New Indications for Electronic Brachytherapy(eBx) at Astro Meeting 3 Xoft Showcases Interim Clincal Results for Breast Cancer Product and New Indications for Electronic Brachytherapy(eBx) at Astro Meeting 4 Enobia Pharma Appoints Industry Veterans with Commercial and Manufacturing Expertise to Expand Senior Management Team 2 Enobia Pharma Appoints Industry Veterans with Commercial and Manufacturing Expertise to Expand Senior Management Team 3

Xoft Showcases Interim Clincal Results for Breast Cancer Product and New Indications for Electronic Brachytherapy(eBx) at Astro Meeting Enobia Pharma Appoints Industry Veterans with Commercial and Manufacturing Expertise to Expand Senior Management Team

(Date:11/20/2009).... 20 /PRNewswire-FirstCall/ - NUCRYST Pharmaceutic...f Shareholders will be held on Monday, December 21...approval of two special resolutions. The first spe...le of all or substantially all of the assets of NU...the asset purchase agreement dated November 10, 20...

(Date:11/20/2009)...tors and Congressmen in Competitive Re-election Ba...ote , Washington, DC (Voc...running for re-election next year in races deemed ...may come to regret voting for House Speaker Nancy ...eaking Zogby International/ O’Leary Report ...

(Date:11/20/2009)...l, November 20 Cardio Va....CVSLMEDICAL.COM , a leading,developer of advanced...d that,the company,s Board of Directors has decide...a and the Far East for its proprietary next-genera...oplasty (PCTA) procedures. , Cardio Vascu...

(Date:11/20/2009)...e November 20 in the Journal of the National Canc...hopes that often appear in news coverage of cancer...h the media and journals to help alleviate the pro... Woloshin, M.D., M.S., of Center for Medicine and ...licy and Clinical Practice in New Hampshire, and B...

(Date:11/20/2009)...d out of Dallas, TX, the new addition to blue sky ...are made in the USA. , Au...ubs is an independent medical scrubs brand which f...n and distribution of hospital uniforms and surgic...cts via their online boutique, the Austin, TX busi...

Breaking Medicine News(10 mins):Health News:NUCRYST Announces Special Meeting of Shareholders 2 Health News:NUCRYST Announces Special Meeting of Shareholders 3 Health News:Just 25% of Voters in Competitive 2010 Senate Races “Much More Likely” to Support Pelosi-Democrats Who Voted for Health Care Bill 2 Health News:Just 25% of Voters in Competitive 2010 Senate Races “Much More Likely” to Support Pelosi-Democrats Who Voted for Health Care Bill 3 Health News:Cardio Vascular Medical Device to Apply for Additional Patents in Europe, Canada and Far East 2 Health News:Promoting healthy skepticism in the news: Helping journalists get it right 2 Health News:Blue Sky Scrubs Secures a Second Texas Manufacturer 2

[0] NUCRYST Announces Special Meeting of Shareholders [0] Just 25% of Voters in Competitive 2010 Senate Races “Much More Likely” to Support Pelosi-Democrats Who Voted for Health Care Bill [0] Cardio Vascular Medical Device to Apply for Additional Patents in Europe, Canada and Far East [0] Promoting healthy skepticism in the news: Helping journalists get it right [0] Blue Sky Scrubs Secures a Second Texas Manufacturer

...a severe form of arterial disease appear to have l...of their diet or smoking habits. Peripheral ar... condition in which fatty build-up accumulates ins...ted with an increased risk of death and disability...

...ents with heart disease are twice as likely to hav... with medication, research suggests. Researchers i... age of 80 who suffered from chronic angina. ...inserted and the balloon inflated to widen the art...

...e often means that areas of the heart muscle becom...th painful angina attacks, and to heart attacks. I...nforce the supply to the heart muscle, this could ...or take months to do so. // Altering a gene...

... a new study obesity does not worsen the outcome i...t failure, experience many problems. Generally in ...e body as efficiently as it should. Even though th... have surveyed 1000 people with heart failure and ...

...has found that the risk of developing a blood clot...ased with the duration of air travel.Like deep vei...clots that are believed to be associated with long...ing care// on arrival at France's busiest internat...

...rugs like it could be making healthy people with n...is prescribed to more than 38 million people world...stries biggest success stories of recent years. Pr...known were hailed as "wonder drugs" when they firs...

Other Medicine News:Health News:Wonder drug - could end in disaster 2

Vitamin C for the heart Surgery a safety in senility Gene therapy - Aim to improve blood flow Is Obesity a risk factor?Blood clots likely in long travel,Wonder drug - could end in disaster

Counter Top Platelet Incubator PC1200

i. Series Floor Model Platelet Incubator PC3200i

Platelet Incubator 3609

Platelet Incubator TPSRI-32

Medicine Products:

Counter Top Platelet Incubator PC1200 i. Series Floor Model Platelet Incubator PC3200i Platelet Incubator 3609 Platelet Incubator TPSRI-32

( CHICAGO June 29 2007 /PRNewswire-Fir...)Advanced Life Sciences to Host Conference Call to Discuss Data From,Cethromycin's First of Two Phase 3 Pneumonia Trials,Health